Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Int J Technol Assess Health Care ; 38(1): e59, 2022 Jun 22.
Artigo em Inglês | MEDLINE | ID: mdl-35730573

RESUMO

OBJECTIVES: This study aimed to identify different criteria for priority setting of rare diseases to help policy makers in making evidence-informed decisions. METHODS: A scoping review was conducted to comprehensively examine the existing various methods and criteria for prioritizing orphan drugs and rare diseases. We performed searching in Scopus, PubMed, Embase, and websites of health technology assessment (HTA) agencies, 2000-21, and data were extracted. RESULTS: From the 1,580 identified publications, eleven articles were included. Multicriteria decision analysis was the most frequent method (seven out of eleven studies) used for priority setting. The extracted criteria for priority setting of orphan products were analyzed based on six main categories as follows: health outcomes and clinical implications (six subsets which showed clinical implications), economic aspects (four subsets that indicated the economic effects of orphan drugs and rare diseases), disease and population characteristics (six subsets that included the characteristics of the rare diseases), therapeutic alternatives and uniqueness of orphan technologies (two subsets which discussed the alternatives and uniqueness of orphan technologies), evidence (three subsets which regarded the quality and availability of evidence), and other criteria (three subsets dealing with social and organizational criteria). Cost-effectiveness, budget impact, and disease severity were the most frequent criteria in the studies. CONCLUSIONS: Because of the high price of orphan drugs and limitations of using HTA for reimbursement of them, it is critical to explore them by precise technical methods like multiple criteria decision making in priority setting.


Assuntos
Produção de Droga sem Interesse Comercial , Doenças Raras , Orçamentos , Análise Custo-Benefício , Humanos , Doenças Raras/tratamento farmacológico , Avaliação da Tecnologia Biomédica/métodos
2.
Iran J Kidney Dis ; 8(3): 185-8, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24878939

RESUMO

Organ transplantation as an undeniable life-saving therapeutic modality fundamentally requires infrastructure, devoted and trained professionals, and positive public attitude to be set up in a well-organized manner at the national level. In addition to sharing achievements and reviewing the increasing trend of transplanted organs in the past 12 years following legislations in Iran, this report raises some concerns from the point of transplantation outcome view.


Assuntos
Transplante de Órgãos/tendências , Obtenção de Tecidos e Órgãos/tendências , Humanos , Irã (Geográfico) , Transplante de Órgãos/estatística & dados numéricos , Garantia da Qualidade dos Cuidados de Saúde/organização & administração , Garantia da Qualidade dos Cuidados de Saúde/tendências , Obtenção de Tecidos e Órgãos/organização & administração
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA